1191PD - Clinical activity of crizotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring ros1 gene rearrangement

Date 30 September 2012
Event ESMO Congress 2012
Session NSCLC, metastatic
Topics Cytotoxic agents
Non-small-cell lung cancer
Biological therapy
Presenter Sai-Hong Ou
Authors S.I. Ou1, R. Camidge2, J. Engelman3, J. Clark4, L. Tye5, K. Wilner5, P. Stephenson6, M. Varella-Garcia7, A. Iafrate4, A. Shaw4
  • 1Cancer Centre, Chao Family Centre, Irvine/US
  • 2University of Colorado, Denver/US
  • 3Massachusetts General Hospital, 2129 - Charlestown/US
  • 4Cancer Center, Massachusetts General Hospital, Boston/US
  • 5Oncology, Pfizer, CA/US
  • 6Chapel Hill,, Rho, Inc., NC/US
  • 7School Of Medicine, University of Colorado, CO/US



Chromosomal rearrangements in the receptor tyrosine kinase (RTK) ROS1 define a new molecular subset of NSCLC. ALK inhibitors can inhibit ROS1 kinase activity in cell lines. We examined the efficacy and safety of crizotinib, a small molecule inhibitor of two other RTKs, MET and ALK, in patients with advanced, ROS1-rearranged NSCLC.


Patients with advanced NSCLC harboring ROS1 rearrangement, as determined using a break-apart FISH assay, were recruited into an expansion cohort of the original phase 1 study of crizotinib. Patients were treated with crizotinib at the standard oral dose of 250 mg BID. The objective response rate (ORR) was determined based on RECIST v1.0. The disease control rate (DCR; stable disease [SD] + partial response [PR] + complete response [CR]) was evaluated at weeks 8 and 16.


At the time of data cut-off on April 19, 2012, 15 patients with ROS1 NSCLC had received crizotinib and 14 were evaluable for response. The median age was 54 years (range 31–72). Fourteen patients were never-smokers and all had adenocarcinoma histology. All patients were confirmed negative for ALK rearrangement. The median number of prior treatments was 1 (range 0–6). The first ROS1 patient received crizotinib on October 19, 2010. To date, the ORR is 57% (8/14; 95% CI 28.9–82.3), with 7 PR and 1 CR. There were 4 SD, one of which was unconfirmed as PR at the time of data cut-off. The DCR at 8 weeks was 79% (11/14). Median duration of treatment was 25.7 weeks (range 0.1 + to 65.3 + ), and 12 patients continue on study. The pharmacokinetics, antitumor activity and safety profile of crizotinib in this group of patients were similar to those observed in patients with ALK-positive NSCLC.


Crizotinib is associated with clinically significant antitumor activity in patients with ROS1 NSCLC. Similar to ALK, ROS1 rearrangement defines another unique molecular subset of NSCLC patients for whom crizotinib therapy may be highly effective. Importantly, this study represents the first clinical investigation of ROS1 as a driver mutation and therapeutic target in cancer.


S.I. Ou: Advisory role: Pfizer, Genentech. Compensated Honoraria: Pfizer, Genentech, Lilly. Myself Research funding: Pfizer. Myself (institution).

D.R. Camidge: Advisory role: Pfizer. Myself. Honoraria: Pfizer. Myself.

L. Tye: Employment: Pfizer. Clinician. Myself. Stock Ownership; Pfizer. Myself.

K. Wilner: Emplyement: Pfizer. Senior Director. Myself. Compensated. Stock ownership: Pfizer. Myself.

M. Varella-Garcia: Honoraria: Abbott Molecular. Myself. funding for the trial provided by NIH - yes.

A.T. Shaw: Advisory role: Pfizer, Ariad, Chugai, Novartis, Daiichi-sankyo. Myself. Compensated Research funding: Astra Zeneca, Novartis. Myself.

All other authors have declared no conflicts of interest.